Bioam Gestion

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

Adocia is a clinical-stage biotechnology company based in Lyons, France, founded in 2005 and known for its focus on tissue regeneration. The company specializes in developing formulations of approved therapeutic proteins and peptides aimed at treating diabetes and other metabolic diseases. Adocia has created a proprietary technology platform called Biochaperone, which enhances the effectiveness of these therapeutic proteins. Its clinical pipeline includes products such as Biochaperone Lispro, Biochaperone Combo, and Biochaperone Glucagon, while its pre-clinical pipeline features BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Additionally, Adocia holds a patent portfolio that primarily addresses chronic wound healing, insulin therapy, and monoclonal antibodies.

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

IntegraGen is a French biotechnology company located in the Genopole life science park in Evry, near Paris. The company specializes in the development of genetic biomarkers and leverages its proprietary technology platforms to provide genomics services to the pharmaceutical industry, biotechnology firms, and research organizations. IntegraGen offers a range of services, including clinical research, bioinformatics, and bioanalysis, as well as solutions for agrigenomics and microbiologic research. With its unique intellectual property and access to extensive sample libraries, IntegraGen aims to advance the understanding and treatment of central nervous system and metabolic diseases.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Ademtech is developing and manufacturing superparamagnetic nanoparticles for in vitro diagnostic and life sciences applications. The association of complementary skills such as physicochemistry, polymer chemistry, immunology, cellular biology, molecular biology, and virology leads to the development of novel nano-objects with unique characteristics. Ademtech offers magnetic media, instruments (thermoshaker, an electronic pipette with variable spacing) and automata (extraction and pipetting). It was founded in 2000 and is headquartered in Pessac, France.